FTC and Impax face off in closing arguments
Teva and Mylan both sell a huge range of generic drugs.
The Federal Trade Commission and Impax squared off on Thursday in a final round of arguments over the pay-for-delay case in the agency’s internal tribunal.
Subscribe to Global Competition Review
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Competition Review experts.
Subscribe now
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10